GPBAR1 and metabolic dysfunction-associated steatohepatitis: A number of bile acid-based therapies, including FXR agonists, TGR5 agonists, bile acid transporter inhibitors, and others, have been developed and show promise for the treatment of non-alcoholic steatohepatitis [144].